New York, United States - May 20, 2022 /MarketersMEDIA/ —
Small molecules that have antiviral activity against SARS-CoV-2 offer therapeutic possibilities for COVID-19. These direct-acting antivirals can target virus-specific proteins and inhibit the virus, but a limited number of direct-acting small molecules have been currently authorized for COVID-19 treatment. Creative Biolabs, as a leading biotech company dedicated to human health improvement, notices the significance of host cellular defense in antiviral infection and explores host-acting antiviral strategies against SARS-CoV-2 along with comprehensive antiviral drug discovery services.
Different from direct-acting antivirals, host-acting antivirals inhibit the virus by targeting host pathways essential for the viral lifecycle, such as viral replication or reproduction in infected cells. Due to less possibility for the virus to develop drug resistance against host-acting antivirals and the plausibility of broad-spectrum antiviral activity against not only SARS-CoV-2 but also several other viruses, Creative Biolabs provides a wide range of broad-spectrum SARS-CoV-2 drug discovery services to facilitate the discovery of anti-SARS-CoV-2 drugs, such as developing interferons α and β as antiviral agents and other therapeutic strategies.
Besides novel antiviral drug discovery, the assessment of medication toxicity and efficacy also plays an important role in identifying and deploying COVID-19 treatments. Creative Biolabs has developed comprehensive platforms for SARS-CoV-2 drug evaluation, including:
- Antiviral Assay for SARS-CoV-2
The repositioning of evaluated drugs is a necessary part of SARS-CoV-2 drug evaluation. Immunofluorescence-based assay for anti-SARS-CoV-2 at Creative Biolabs allows researchers to observe morphological changes in cells or at sites of viral replication under a physiological condition. The immunofluorescence-based antiviral assay is an alternative method with fewer steps, shorter times, and lower variability for detecting viruses that have rapid replication kinetics like SARS-CoV-2.
- Animal Models in Antiviral Candidates Evaluation
Animal models for virus-related diseases have proven to help evaluate disease activity, detect mechanisms and factors responsible for the disease progress, as well as assess the safety of candidate drugs in clinical use. Scientists at Creative Biolabs can generate animal models of SARS-CoV-2 infection using different virus strains, virus dosages, or virus inoculation to mimic the natural pathogenesis of SARS-CoV-2, helping investigate SARS-CoV-2 cytokine and chemokine responses.
About Creative Biolabs
US-based Creative Biolabs is a leading life science company experienced in vaccine development and antiviral research. It makes contributions to controlling the COVID-19 pandemic through reliable and comprehensive drug discovery services for SARS-CoV-2, such as novel drug candidate screening, neutralizing antibody development, and inhibitors discovery.
To seek necessary support for antiviral discovery from initial discovery, and preclinical research to in vitro diagnostic (IVD) exploration, please contact Creative Biolabs.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://sars-cov-2.creative-biolabs.com
Release ID: 89075423
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.
